Search | Clinical Trials Finder

Conditions: Anterior Ischemic Optic Neuropathy
Interventions: Diagnostic procedures; Drug
Lead sponsor: Bayer; Industry
Eligibility: 40 Years and older · Male only
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2018
U.S. locations: 11
States / cities: Vista, California • Atlantis, Florida • Fort Myers, Florida + 7 more

Conditions: Hearing Loss, Hearing Loss, Age-Related, Hearing Disability, Delirium, Delirium in Old Age, Delirium of Mixed Origin, Delirium With Dementia, Delirium on Emergence, Delirium, Cause Unknown, Delirium Superimposed on Dementia, Delirium Confusional State, Delirium;Non Alcoholic, Hearing Loss, Bilateral, Hearing Loss, Sensorineural, Hearing Loss, Functional, Hearing Loss, High-Frequency, Hearing
Interventions: Communication Signage, Amplifier Use; Behavioral
Lead sponsor: Johns Hopkins University; Other
Eligibility: 65 Years and older
Enrollment: 1,543 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Age-related Macular Degeneration, Depression
Interventions: BA-LVR, ST-LVR; Behavioral
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 65 Years and older
Enrollment: 188 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Visual Field Defect, Peripheral, Stroke, Visual Impairment, Hemianopsia, Quadrantanopia, Cortical Blindness, Visual Field Defect Homonymous Bilateral, Occipital Lobe Infarct, Visual Fields Hemianopsia
Interventions: transcranial random noise stimulation (tRNS), Computer Based Visual Training, Sham stimulation, Virtual Reality Based Visual Training; Device · Behavioral
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years to 80 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Central Vision Loss From Macular Diseases
Interventions: Interdisciplinary Low Vision Service, Basic Low Vision Service; Other
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 323 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 7
States / cities: Hines, Illinois • Baltimore, Maryland • Cincinnati, Ohio + 4 more

Conditions: Central Visual Impairment, Macular Degeneration
Interventions: Condition 1: Training visual sensitivity, Condition 2: Training spatial integration, Condition 3: Training spatial attention, Condition 4: Combination training; Behavioral
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years to 30 Years
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 2
States / cities: Birmingham, Alabama • Riverside, California

Conditions: Diabetic Retinopathy
Interventions: PDS Implant Pre-Filled with 100 mg/mL Ranibizumab, Intravitreal Ranibizumab 0.5 mg Injection; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 174 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 64
States / cities: Mesa, Arizona • Phoenix, Arizona • Bakersfield, California + 59 more

Conditions: Optic, Atrophy, Hereditary, Leber
Interventions: GS010, Sham Intravitreal Injection; Biological · Device
Lead sponsor: GenSight Biologics; Industry
Eligibility: 15 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 3
States / cities: Los Angeles, California • Atlanta, Georgia • Philadelphia, Pennsylvania

Conditions: Vision Loss Partial, Vision; Loss, Both Eyes, Hemianopia Homonymous, Hemianopia, Quadrantanopia, Stroke, Ischemic, Stroke - Occipital Infarction, Cortical Blindness
Interventions: Training in the Blind Field; Device
Lead sponsor: University of Rochester; Other
Eligibility: 21 Years to 80 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2032
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Optic Neuritis
Interventions: Clemastine, Placebo; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 55 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2028
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Central Visual Impairment, Macular Degeneration
Interventions: Training visual sensitivity, Combination training; Behavioral
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years to 89 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Retinal Vein Occlusion
Interventions: Aflibercept Ophthalmic; Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Hearing and Vision Loss
Interventions: Fitting algorithm; Other
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years to 80 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Retinal Disease, Age-Related Macular Degeneration, Retinitis Pigmentosa, Stargardt Disease, Optic Neuropathy, Nonarteritic Ischemic Optic Neuropathy, Optic Atrophy, Optic Nerve Disease, Glaucoma, Leber Hereditary Optic Neuropathy, Blindness, Vision Loss Night, Vision Loss Partial, Vision, Low, Retinopathy, Maculopathy, Macular Degeneration, Retina Atrophy
Interventions: Arm 1; Procedure
Lead sponsor: MD Stem Cells; Industry
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2028
U.S. locations: 2
States / cities: Westport, Connecticut • Coral Springs, Florida

Conditions: Blindness
Interventions: Electrotactile display (BrainPort), Vision-to-sound converter (AI Sight), Sham; Device
Lead sponsor: Stanford University; Other
Eligibility: 8 Years to 85 Years
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2030
U.S. locations: 2
States / cities: Palo Alto, California • Stanford, California

Conditions: Relative Afferent Pupil Defect (RAPD)
Interventions: Swinging Light test, Virtual Reality Head-Mounted Display (VR HMD); Diagnostic Test
Lead sponsor: The University of Texas Medical Branch, Galveston; Other
Eligibility: 18 Years to 85 Years
Enrollment: 71 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Galveston, Texas

Conditions: Brain Injuries, Visually Impaired Persons
Interventions: Vision Restoration Therapy, NVT Eye Scanning Therapy, Eccentric Viewing Training, Sham; Other · Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 20 Years to 79 Years
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Retinitis Pigmentosa
Interventions: Electro-acupuncture; Procedure
Lead sponsor: Johns Hopkins University; Other
Eligibility: 10 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Cortical Blindness, Stroke Ischemic, Vision Loss Partial, Visual Fields Hemianopsia, Hemianopia, Hemianopia Homonymous, Occipital Lobe Infarct
Interventions: MRI; Diagnostic Test
Lead sponsor: University of Rochester; Other
Eligibility: 21 Years to 80 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Age-related Macular Degeneration (AMD)
Interventions: Study-specific rehabilitation (SSR) procedures; Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 50 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Augusta, Georgia

Conditions: Visual Loss
Interventions: audiovisual educational intervention; Other
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 89 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Vision Loss
Interventions: Not listed
Lead sponsor: University of Nebraska; Other
Eligibility: 7 Years to 50 Years
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Diabetic Macular Edema
Interventions: Ruboxistaurin, Placebo; Drug
Lead sponsor: Chromaderm, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 309 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 19
States / cities: Phoenix, Arizona • Artesia, California • Newark, Delaware + 16 more

Conditions: Diabetic Macular Edema
Interventions: LKA651, Lucentis; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 7
States / cities: Beverly Hills, California • Rancho Cordova, California • Miami, Florida + 4 more

Search by objective public record fields.

PDE5 Inhibitor Use and Non-arteritic Anterior Ischemic Optic Neuropathy (NAION)

Sight and Hearing Investigation Into Effects on Delirium

Low Vision Depression Prevention Trial for Age Related Macular Degeneration

Improving Visual Field Deficits With Noninvasive Brain Stimulation

Low Vision Intervention Trial II (LOVIT II)

Factors in Learning And Plasticity: Healthy Vision

A Multicenter, Randomized Study in Participants With Diabetic Retinopathy Without Center-involved Diabetic Macular Edema To Evaluate the Efficacy, Safety, and Pharmacokinetics of Ranibizumab Delivered Via the Port Delivery System Relative to the Comparator Arm

Efficacy Study of GS010 for Treatment of Vision Loss From 7 Months to 1 Year From Onset in LHON Due to the ND4 Mutation (REVERSE)

Effect of Visual Retraining After Stroke

Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)

Factors in Learning And Plasticity: Macular Degeneration

Vascular Endothelial Growth Factor (VEGF) Levels in Retinal Vein Occlusion (RVO) During Anti-VEGF Treatment

Validating a Self-fitting Hearing Aid

Stem Cell Ophthalmology Treatment Study II

Sensory Substitution and Brain Plasticity Following Vision Loss

Measuring Relative Afferent Pupillary Defect

Functional Vision in TBI

Acupuncture for the Treatment of Vision Loss Due to Retinitis Pigmentosa

Mechanisms of Visual Restoration After Occipital Stroke

Rehabilitating Vision Loss in Veterans With Age-Related Macular Degeneration

Evaluation of a Scalable Educational Intervention for Adjustment and Coping to Vision Loss

First-Sight Refractive Error Correction in the Developing World

Effect of Ruboxistaurin on Clinically Significant Macular Edema

Multiple Dose Safety and Efficacy of LKA651 in Patients With Diabetic Macular Edema